STUDY DESIGN
Diabetes
CVD, BLOOD, TYPE 2 DIABETES, DIABETES
The BPROAD study is a multicenter, outcome assessor blinded, randomized controlled trial (ClinicalTrials.gov Identifier: NCT03808311) that will enroll 12 702 type 2 diabetes patients with elevated systolic BP and increased CVD risk from 150 study centers across mainland China to undergo randomly antihypertensive treatment achieving systolic BP <120 mm Hg or systolic BP <140 mm Hg for up to 5 years (Figure CONSORT diagram of the BPROAD study. BPROAD, Blood Pressure Control Target in Diabetes; CONSORT, Consolidated Standards of Reporting Trials; SBP, systolic blood pressure.